SCHEDULE 13D: Apeiron Investment Group and Christian Angermayer Boost Stake in ATAI Life Sciences to 22.7% Following $55 Million Offering

Apeiron Investment Group and its controlling shareholder Christian Angermayer have significantly increased their beneficial ownership in ATAI Life Sciences N.V. to 22.7% following the company's recent $55 million registered offering.

Summary

• Apeiron Investment Group Ltd. and its affiliates, including Christian Angermayer, have filed a Schedule 13D, disclosing their increased beneficial ownership in ATAI Life Sciences N.V.
• The reporting persons collectively beneficially own 44,908,967 Common Shares, representing approximately 22.7% of the Issuer's outstanding shares as of February 14, 2025.
• This increase follows ATAI Life Sciences' registered offering, which closed on February 14, 2025, raising approximately $55,000,000 gross proceeds from the sale of 26,190,477 Common Shares at $2.10 per share, plus an additional 3,928,571 shares from the underwriter's option exercise.
• Apeiron purchased 10,835,718 Common Shares in the offering for approximately $22,750,000, funded by facility agreements with Alien Capital Limited and Joh. Berenberg, Gosser & Co. KG.
• Apeiron has pledged the newly acquired 10,835,718 shares to Alien Capital and has also pledged 28,364,432 previously held shares and convertible notes to Tether International Limited to secure loan obligations.
• Christian Angermayer has provided personal guarantees for the facility agreements with Alien and Tether.
• The reporting persons state their acquisition is for investment purposes and may lead to discussions about extraordinary corporate transactions, including mergers, asset sales, or changes to management or the Board.

Sentiment

Score: 7

Explanation: The significant increase in beneficial ownership by a key investor and the successful capital raise are positive indicators of confidence and financial strengthening. However, the extensive use of pledged shares and personal guarantees introduces a degree of financial risk and leverage for the reporting persons.

Positives

• Significant investment by a major shareholder (Apeiron and Christian Angermayer) demonstrates continued confidence in ATAI Life Sciences.
• Christian Angermayer's extended consultancy agreement suggests ongoing strategic involvement and guidance.
• The capital raise itself provides the Issuer with approximately $55,000,000 in gross proceeds.

Negatives

• A substantial portion of Apeiron's holdings (including newly acquired shares) are pledged as collateral for loan facilities, potentially indicating financial leverage.
• Christian Angermayer has provided personal guarantees for significant loan amounts, linking his personal financial risk to the company's performance and Apeiron's loan obligations.
• Apeiron is subject to a 90-day lock-up agreement, restricting sales of shares acquired before the offering.

Risks

• Financial Leverage and Pledged Shares: Apeiron's reliance on facility agreements and the pledging of a significant portion of its ATAI shares as collateral could lead to forced sales if loan obligations are not met.
• Personal Guarantees: Christian Angermayer's personal guarantees expose him to direct financial liability for Apeiron's loan obligations, which could indirectly impact his involvement or investment in ATAI.
• Market Conditions: The value of the pledged shares is subject to market fluctuations, which could affect the security of the loans and Apeiron's financial position.
• Potential for Corporate Actions: The reporting persons' stated intent to potentially seek extraordinary corporate transactions (merger, asset sales, management changes) introduces uncertainty regarding the company's future structure and strategy.

Future Outlook

The reporting persons intend to review their investments on a continuing basis and may acquire additional securities, sell existing holdings, or engage in discussions with management and the Board regarding potential extraordinary corporate transactions, including mergers, asset sales, changes to capitalization, or changes in management or Board composition. Christian Angermayer's consultancy agreement is extended until January 5, 2028, indicating his continued strategic involvement.

Management Comments

• "The Reporting Persons acquired the securities described in this Schedule 13D for investment purposes and intend to review their investments in the Issuer on a continuing basis."
• "Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons' review of numerous factors, including... an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments."
• "The Reporting Persons and their designees to the Board may engage in discussions with management, the Board, and securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or other transaction that could result in the de-listing or de-registration of the Common Shares; sales or acquisitions of assets or businesses; changes to the capitalization or distribution policy of the Issuer; or other material changes to the Issuer's business or corporate structure, including changes in management or the composition of the Board."

Industry Context

This filing indicates a significant, leveraged investment by a key shareholder in ATAI Life Sciences, a company likely operating in the biotechnology or pharmaceutical sector, possibly with a focus on psychedelic medicine given its name. The substantial capital raise and the investor's intent to potentially influence corporate strategy suggest a dynamic environment where strategic investments and potential restructuring are key themes.

Comparison to Industry Standards

• This document primarily details a change in beneficial ownership and related financing, rather than operational or financial performance metrics that would typically be compared to industry standards.
• The significant stake (22.7%) held by a single investment group and its controlling individual is notable, indicating a concentrated ownership structure. This level of ownership often grants substantial influence, which is common for early-stage or growth companies where founding investors maintain large stakes, but less common for mature, widely held public companies.
• The use of pledged shares for financing is a common practice in leveraged investments, but the extent of pledging across multiple lenders (Alien, Tether, other banks) and personal guarantees by the controlling shareholder (Christian Angermayer) suggests a high degree of financial commitment and leverage, which could be higher than typical for less concentrated, diversified institutional investors.

Corporate Governance

Related Party Transactions

• Christian Angermayer, as the controlling shareholder of Apeiron Investment Group, has a consultancy agreement with ATAI Life Sciences AG (the Issuer's operating subsidiary), which was extended and expanded until January 5, 2028.
• Christian Angermayer has provided personal guarantees for facility agreements between Apeiron and Alien Capital Limited, and between Apeiron and Tether International Limited, securing Apeiron's loan obligations.
• Apeiron Investment Group, controlled by Christian Angermayer, is a significant shareholder of ATAI Life Sciences N.V. and participated substantially in the recent registered offering.

Stakeholder Impact

• Shareholders: Experience dilution from the recent offering but benefit from the company raising capital. The increased stake and potential strategic influence of Apeiron/Angermayer could lead to significant corporate actions, impacting future share value.
• Lenders (Alien, Berenberg, Tether): Their loans to Apeiron are secured by a substantial portion of ATAI Life Sciences shares, and in some cases, personally guaranteed by Christian Angermayer, providing a degree of security for their investments.
• Company Management/Board: May face increased engagement and potential pressure from Apeiron and Christian Angermayer regarding strategic direction, corporate structure, and management composition.
• Employees: Potential corporate transactions or changes in strategy could impact employees, though no direct impact is specified.

Next Steps

• Reporting Persons will continue to review their investment in ATAI Life Sciences.
• Reporting Persons may acquire additional securities or sell existing holdings.
• Reporting Persons may engage in discussions with management, the Board, and securityholders regarding potential extraordinary corporate transactions (e.g., merger, asset sales, changes to capitalization, management, or Board composition).
• Christian Angermayer's additional stock options are expected to vest around March 7, 2025.
• Apeiron is subject to a 90-day lock-up period from February 12, 2025, restricting sales of certain shares.

Key Dates

Recommendation

Keywords

ATAI Life Sciences, Schedule 13D, Apeiron Investment Group, Christian Angermayer, Shareholder Stake, Beneficial Ownership, Capital Raise, Registered Offering, Pledged Shares, Corporate Governance, Investment Strategy, Biotechnology, Psychedelic Medicine